Pharmacotherapy of osteoporosis 1

Published on August 31, 2015   37 min

Other Talks in the Series: Bone in Health and Disease

Please wait while the transcript is being prepared...
Hello. I'm Dr. Michael McClung, the director of the Oregon Osteoporosis Center in Portland, Oregon. I'm very happy to be a part of this Henry Stewart Talk series entitled bone in health and disease. The series editor, Professor Compston, has asked me to address the topic of pharmacotherapy of osteoporosis.
On the next slide are listed my current financial disclosures. I have relationships with several of the drug companies that make the drugs that we'll be discussing today. Over the past 20 years, I and my center have been involved with clinical studies with virtually all of the drugs that are approved for osteoporosis, and at least in that context, have had a financial relationship with those companies.
In previous parts of this series, the definition of osteoporosis has been described. It is a disorder that is due to bone loss that results in a damage to the architecture of the skeleton, resulting in a weakening of the skeleton and an increased risk of fracture. The objectives of pharmacotherapy are twofold. The primary objective is to protect the patient from fracture, and to reduce the risk of fractures by strengthening the skeleton. There are patients who are not at high risk for fracture, but who are about to experienced rapid bone loss. And there are instances when some drugs are used for a short time to prevent the rapid bone loss that may be occurring in certain patients. And we'll talk about that a little later in the presentation.